| Title: |
COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database |
| Authors: |
Keh, Ryan Y S; Scanlon, Sophie; Datta-Nemdharry, Preeti; Donegan, Katherine; Cavanagh, Sally; Foster, Mark; Skelland, David; Palmer, James; Machado, Pedro M; Keddie, Stephen; Carr, Aisling S; Lunn, Michael P; Manji, Hadi; Lavin, Tim; Lilleker, James B; Gosal, David; Hadden, Robert DM; Watson-Fargie, Taylor; Brennan, Kathryn; Themistocleous, Andreas; Deeb, Jacquie; Romeiro, Ana; Mehta, Puja R; Kullmann, Dimitri; Miller, James; Elsaddig, Amar; Molyneux, Adam; Georgiev, Plamen; Ben-Joseph, Aaron; Holt, James; Roelofs, Jacob; Alkufri, Fadi; Allen, David; Shields, Simon; Murphy, Stephen; Sivasathiaseelan, Harri; Sylvester, Richard; Al-Saleh, Abdul; Roberts, Rhys; Nithi, Kannan; Handdunnethi, Lahiru; Wannop, Kate; Batla, Amit; Sadnicka, Anna; Sivaganasundaram, Jananee; Yermakova, Tatyana; Dasari, Ravi; Quattrocchi, Graziella; Ball, Harriet; Cooper, Rebecca |
| Contributors: |
National Institute for Health Research; University College London Hospitals; Biomedical Research Centre; GBS-CIDP Foundation International |
| Source: |
Brain ; volume 146, issue 2, page 739-748 ; ISSN 0006-8950 1460-2156 |
| Publisher Information: |
Oxford University Press (OUP) |
| Publication Year: |
2022 |
| Description: |
Vaccination against viruses has rarely been associated with Guillain-Barré syndrome (GBS), and an association with the COVID-19 vaccine is unknown. We performed a population-based study of National Health Service data in England and a multicentre surveillance study from UK hospitals to investigate the relationship between COVID-19 vaccination and GBS. Firstly, case dates of GBS identified retrospectively in the National Immunoglobulin Database from 8 December 2021 to 8 July 2021 were linked to receipt dates of COVID-19 vaccines using data from the National Immunisation Management System in England. For the linked dataset, GBS cases temporally associated with vaccination within a 6-week risk window of any COVID-19 vaccine were identified. Secondly, we prospectively collected incident UK-wide (four nations) GBS cases from 1 January 2021 to 7 November 2021 in a separate UK multicentre surveillance database. For this multicentre UK-wide surveillance dataset, we explored phenotypes of reported GBS cases to identify features of COVID-19 vaccine-associated GBS. Nine hundred and ninety-six GBS cases were recorded in the National Immunoglobulin Database from January to October 2021. A spike of GBS cases above the 2016–2020 average occurred in March–April 2021. One hundred and ninety-eight GBS cases occurred within 6 weeks of the first-dose COVID-19 vaccination in England [0.618 cases per 100,000 vaccinations; 176 ChAdOx1 nCoV-19 (AstraZeneca), 21 tozinameran (Pfizer) and one mRNA-1273 (Moderna)]. The 6-week excess of GBS (compared to the baseline rate of GBS cases 6–12 weeks after vaccination) occurred with a peak at 24 days post-vaccination; first-doses of ChAdOx1 nCoV-19 accounted for the excess. No excess was seen for second-dose vaccination. The absolute number of excess GBS cases from January–July 2021 was between 98–140 cases for first-dose ChAdOx1 nCoV-19 vaccination. First-dose tozinameran and second-dose of any vaccination showed no excess GBS risk. Detailed clinical data from 121 GBS patients were ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1093/brain/awac067 |
| DOI: |
10.1093/brain/awac067/47057028/awac067.pdf |
| Availability: |
https://doi.org/10.1093/brain/awac067; https://academic.oup.com/brain/advance-article-pdf/doi/10.1093/brain/awac067/47057028/awac067.pdf; https://academic.oup.com/brain/article-pdf/146/2/739/49171686/awac067.pdf |
| Rights: |
https://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.755A268 |
| Database: |
BASE |